Biosergen AB (publ) (STO:BIOSGN)
Sweden · Delayed Price · Currency is SEK 1.360
-0.010 (-0.73%)
Sep 4, 2026, 12:38 PM CET
Biosergen AB Revenue
Biosergen AB had revenue of 2.09M SEK in the twelve months ending June 30, 2026, down -23.35% year-over-year. In the year 2025, Biosergen AB had annual revenue of 2.09M with 7.63% growth.
Revenue
2.09M
Revenue Growth
-23.35%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
1
Market Cap
3.22M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.09M | 148.00K | 7.63% |
| Dec 31, 2024 | 1.94M | -7.44M | -79.31% |
| Dec 31, 2023 | 9.38M | 4.20M | 80.94% |
| Dec 31, 2022 | 5.18M | -3.39M | -39.54% |
| Dec 31, 2021 | 8.57M | 4.14M | 93.43% |
| Dec 31, 2020 | 4.43M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Magle Chemoswed Holding AB | 275.79M |
| ExpreS2ion Biotech Holding AB | 24.25M |
| Fluicell AB | 22.19M |
| AcouSort AB | 9.31M |
| OncoZenge AB | 5.97M |
| NanoEcho AB | 1.13M |
| Alligator Bioscience AB | 681.00K |
| Pila Pharma AB | 275.74K |
Biosergen AB News
- 16 days ago - Biosergen AB Quarterly report: Q2 2026 - Filings
- 6 months ago - Biosergen AB Quarterly report: Q4 2025 - Filings
- 6 months ago - Biosergen AB Annual report: Q4 2025 - Filings
- 9 months ago - Biosergen AB Quarterly report: Q3 2025 - Filings